1 / 24

Platinum series: best papers on RCC in 2013

Platinum series: best papers on RCC in 2013. Dr. Camillo Porta S.C. di Oncologia Medica I.R.C.C.S. Policlinico San Matteo , Pavia. What I wanted to tell you about … but I can’t. The final publication of the COMPARZ trial (already accepted by the NEJM).

bill
Download Presentation

Platinum series: best papers on RCC in 2013

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Platinum series: best papers on RCC in 2013 Dr. Camillo Porta S.C. di OncologiaMedica I.R.C.C.S. Policlinico San Matteo, Pavia

  2. WhatI wanted to tellyouabout … but I can’t The final publication of the COMPARZ trial (already accepted by the NEJM) The final publication of the PISCES trial (revision just submitted to the JCO)

  3. Content of the presentation Therapeutics final results of the AXIS trial TKI-mTORI-TKI or TKI-TKI-mTORI? selection criteria for immunotherapy and its efficacy post-TKIs Prognostic criteria validation of the Heng’s score prognostic factors for survival in Sunitinib-treated patients Translational research Sunitinib Tx and tumor growth

  4. The AXIS trial

  5. AXIS trial final OS results

  6. AXIS trial final OS results: overall patient population

  7. AXIS trial final OS results: other analyses Post Sunitinib Post cytokines

  8. AXIS trial results: Patient Reported Outcomes

  9. AXIS trial results: no differences in PROs

  10. Which sequence over 3 lines of treatment?

  11. Few patients receive 3 drugs, but the winner is …

  12. Targeted agents after high-dose IL-2 immunotherapy

  13. High-dose IL-2 immunotherapy: which patients?

  14. High-dose IL-2 immunotherapy after targeted agents Does these results really mean something?

  15. Validation of the Heng’s criteria

  16. Different models compared

  17. And the winner is …

  18. Prognostic factors for survival in Sunitinib treated pts

  19. Prognostic factors for Sunitinib: nihil novo sub solem Motzer RJ et al. BJC 2013

  20. Sunitinib and tumor growth

  21. Is a strong angiogenesis inhibition linked to a rapid tumor progression?

  22. Sunitinib does not alter tumor biology in vivo

  23. Thank You for Your kind attention!!! c.porta@smatteo.pv.it

More Related